W2G BIOPHARMA
Unlocking BIoTheraputics
Introducing Our New Brands
Advancing Medical Therapy & Innovation
W2G
-
1 in 4 will suffer from Mental Illness
-
1 in 5 will suffer from Depression
-
1 in 5 will suffer from Addiction
It’s Time To Change The Way We Look At Medicine…
Medical Thinking Redesigned
Organic Production
HIGHLIGHTS
Psilocybin Dealer License Confirmed For Nov 8, 2021
Cannabis License Received Nov 2020
Cannabis Operations Commence Jan 2021
Over 35 New Genetic Cannabis Strains
Cannabis Sales Begin April 2021
Cannabis + Psilocybin Cultivation
We believe wellness starts with a standardized organic growth plan. By combining our expertise in organic cultivation technology, proprietary genetics and our experienced OKO Genetic team, Way2Grow Biopharma is able to grow the highest quality, terpene rich, consistent organic medical cannabis.
Tissue Culture Lab
We customize medical grade organic strains in a completely sterile production environment while reducing disease, pests, and pathogens. Our small batch approach focuses on cultivar specific environments to apply a refining, stabilizing, and purifying methodology to customize cultivars for specific medical needs.
Micropropagation
HIGHLIGHTS
Cannabis License received Nov/2020
Cannabis Tissue culture Lab operational Feb 2021
Pre-Orders start Feb 2021
Genetic Leasing & Sales Begin April/May 2021
Psilocybin Tissue Culture anticipated
November 8, 2021
Cannabis + Psilocybin Extraction
W2G received a Standard Cannabis Cultivation License toward the end of 2020. At W2G we focus on isolating the THC, CBD, Terpenes and Cannabinoids from the cannabis flower to give our medical patients the richest organic medical extracts available.
Science & Innovation
It is believed that some psychedelics such as psilocybin mushrooms, may help re-focus old behaviour patterns and build new and healthier ones as seen from the creation of new neural pathways. By standardizing growth plans and extraction techniques, we are developing more consistent standards used in the production and extraction of psilocybin mushrooms for medical use.
Psilocybin Application (Submitted) January 2020
Section 56 Research Exemption Submission (Pending)
Research Laboratory Summer 2021
Psilocybin License Pending - November 8, 2021
Research Laboratory
HIGHLIGHTS
Medical Sales + Global Distribution
Medical Sales License & EU-GMP Facilities allow for import/export product to/from other medically licensed facilities internationally.
W2G Biopharma has a specialized team to draw up the import and export license paperwork to ensure we meet compliance and regulatory framework to import and export our W2G organic products.
W2G is developing strong strategic global partnerships to promote safe and responsible production and distribution of cannabis products.